BiotechTube
Glycotest Diagnostics

Glycotest Diagnostics

Baltimore, United States· Est.
glycotest.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Glycotest Diagnostics is a private, pre-revenue biotech focused on transforming liver disease diagnostics through its unique platform measuring abnormal fucosylation of serum glycoproteins. Its lead program is the HCC Panel, designed for early detection of hepatocellular carcinoma, which has shown promising preliminary clinical data outperforming the current standard (AFP) and is undergoing a 776-patient validation study. Backed by NetScientific and EMV Capital, Glycotest targets a large and growing global market of patients at risk from viral hepatitis and metabolic liver diseases like NASH, aiming to address a critical unmet need for sensitive, early-stage detection.

OncologyHepatology

Technology Platform

Proprietary glycomic platform measuring abnormal fucosylation patterns on serum glycoproteins to detect and differentiate liver cancers and fibrosis-cirrhosis from standard blood samples.

Funding History

2
Total raised:$12M
Grant$2M
Series A$10M

Opportunities

The global epidemic of metabolic liver disease (NASH/MASLD) is creating a vast, growing population requiring lifelong surveillance for liver cancer, driving demand for better diagnostics.
Glycotest's unique glycobiology approach targets the critical unmet need for sensitive early-stage HCC detection, where current standards fail, allowing for curative intervention and commanding significant market value.
The platform's potential extends beyond HCC to other liver diseases like cholangiocarcinoma and fibrosis-cirrhosis.

Risk Factors

The company faces significant clinical risk as its lead HCC Panel's success depends on the outcome of a single, pivotal 776-patient validation study.
Commercialization presents major challenges, including establishing reimbursement, building a sales force, and driving physician adoption in a competitive landscape.
As a pre-revenue company, Glycotest remains reliant on securing additional investment to fund operations through to regulatory approval and launch.

Competitive Landscape

Glycotest competes in the liquid biopsy and early cancer detection space, facing potential competition from large diagnostic firms (e.g., Exact Sciences) and well-funded startups developing multi-cancer early detection tests. Its direct competition includes other companies focusing on liver cancer biomarkers, such as those improving upon or combining AFP with other markers. Glycotest's key differentiator is its unique focus on glycoprotein fucosylation patterns, a novel disease signal not widely exploited by competitors.

More companies in Diagnostics & Precision Medicine →More companies in United States →